Tenax Therapeutics
Tenax Therapeutics reported revenue of $0 million in fiscal 2025. The diluted share count rose 156.8%.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Tenax Therapeutics lost money in fiscal 2025: a net loss of $53 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 6 | 2 | 10 | 95 | 98 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −34,487.1x | 2,487.7x | −343.1x | −847.6x | — |
| Current ratio | 3.6x | 1.7x | 3.3x | 20.6x | 14.6x |
| Quick ratio | 3.6x | 1.7x | 3.3x | 20.6x | 14.6x |
Cash flow
Projections
Project Tenax Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 6 insiders bought $5.0 million of Tenax Therapeutics shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 16, 2026 | Declan DooganDirector | Bought | 53,000 | $1.92 | $101,760 | Form 4 |
| Sep 15, 2026 | Christopher Thomas GiordanoCEO, Director | Bought | 4,850 | $1.82 | $8,827 | Form 4 |
| Sep 11, 2026 | Christopher Thomas GiordanoCEO, Director | Bought | 6,000 | $1.88 | $11,280 | Form 4 |
| Sep 11, 2026 | Thomas R Staab IIChief Financial Officer | Bought | 5,675 | $1.94 | $11,010 | Form 4 |
| Sep 3, 2026 | ADAR1 Capital Management LLC10% owner | Bought | 900,000 | $1.78 | $1.6 million | Form 4 |
| Sep 2, 2026 | Daniel Schneeberger10% owner | Bought | 187,704 | $1.80 | $337,867 | Form 4 |
| Sep 1, 2026 | Daniel Schneeberger10% owner | Bought | 179,058 | $1.80 | $322,304 | Form 4 |
| Aug 31, 2026 | Daniel Schneeberger10% owner | Bought | 403,571 | $1.79 | $722,392 | Form 4 |
| Aug 24, 2026 | Daniel Schneeberger10% owner | Bought | 107,374 | $1.75 | $187,904 | Form 4 |
| Aug 21, 2026 | Daniel Schneeberger10% owner | Bought | 716,369 | $1.77 | $1.3 million | Form 4 |
| Aug 20, 2026 | Daniel Schneeberger10% owner | Bought | 202,124 | $1.78 | $359,781 | Form 4 |
| Dec 9, 2025 | Stuart RichChief Medical Officer, Director | Bought | 2,500 | $10.22 | $25,550 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | — | — |
| Altman Z'' | −80.75 | 14.85 | 5.22 |
| Accruals ratio | −23.9% | −5.2% | −16.7% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Pass | Fail |
| Share count didn't rise | — | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | — | Fail |
| F-score | — | — | — |
Compare
Put Tenax Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Tenax Therapeutics | FY25 | — | — | — | — | — | — | |
| Aardvark Therapeutics | FY25 | — | — | — | — | — | — | Compare |
| ABVC BioPharma | FY25 | −41.9% | −2,416.0% | — | — | — | — | Compare |
| Acadia Pharmaceuticals | FY25 | 11.9% | 9.8% | 9.8% | — | — | — | Compare |
| Aclaris Therapeutics | FY25 | −58.2% | −975.9% | −603.4% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 0 | — | — | — | — | — | — | — | 0 | 0 |
| Revenue growth | −100.0% | — | — | — | — | — | — | — | — | — |
| Gross profit | 0 | — | — | — | — | — | — | — | — | — |
| Research and development | 13 | 4 | 1 | 4 | 5 | 25 | 5 | 3 | 13 | 33 |
| Operating income | −53 | −9 | −7 | −9 | 10 | −33 | 11 | −8 | −20 | −56 |
| Net income | −44 | −9 | −14 | −8 | −10 | −32 | 11 | −8 | −18 | −53 |
| Diluted EPS (US$) | — | −6.27 | −9.04 | −1.35 | −0.95 | −1.58 | — | −31.04 | −1.15 | −1.34 |
| Diluted shares (millions) | 1 | 1 | 2 | 6 | 10 | 21 | — | 0 | 15 | 39 |
| Cash flow | ||||||||||
| Cash from operations | −16 | −12 | −6 | −8 | −9 | −11 | −11 | −6 | −15 | −36 |
| Capital expenditure | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | — |
| Free cash flow | −16 | −12 | −6 | −8 | −9 | −11 | −11 | — | — | — |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 22 | 22 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 0 | 0 | 0 | — | — | — | 0 | 1 | 19 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 13 | 8 | 13 | 5 | 7 | 6 | 2 | 10 | 95 | 98 |
| Debt incl. finance leases | 0 | 0 | 0 | 0 | 0 | — | — | — | — | — |
| Total assets | 23 | 10 | 13 | 6 | 7 | 6 | 3 | 12 | 97 | 104 |
| Total liabilities | 6 | 1 | 2 | 3 | 2 | 2 | 2 | 4 | 5 | 7 |
| Shareholders' equity | 17 | 9 | 12 | 4 | 5 | 4 | 2 | 8 | 92 | 97 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| Free cash flow margin | — | — | — | — | — | — | — | — | — | — |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — | — | — | — | — |
| Return on capital | −145.3% | −290.0% | — | — | — | — | — | — | — | — |
| Return on equity | −100.3% | −67.9% | −137.0% | −108.0% | −234.6% | −732.2% | 385.1% | −160.8% | −35.2% | −55.6% |
| Return on assets | −82.7% | −53.2% | −121.8% | −85.2% | −148.9% | −505.0% | 235.1% | −102.2% | −32.5% | −52.4% |
| Net debt to EBITDA | — | — | — | — | −0.7x | — | — | — | — | — |